GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy

GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010